When Albert Bourla succeeds Ian Read as Pfizer Inc.'s CEO on Jan. 1, he'll take over the world's largest pharmaceutical company at a time when it enjoys several strong growth drivers (Eliquis, Ibrance, Xeljanz and Xtandi) but faces equally potent challenges in its key product areas.
The CEO transition itself promises to be a smooth one even as the road ahead may be daunting. Bourla was...








